Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form
Working Towards Quality Medical Care for the Future

COPD Clinical Trial

QCR has a study for moderate to severe COPD patients, evaluating the efficacy, safety and tolerability of Dupilumab, an investigational biological monoclonal antibody.

The study has 2 treatment arms: Dupilumab and placebo and patients will be randomized in a 1:1 fashion. Dupilumab and placebo are administered as subcutaneous injections once every 2 weeks, for up to 52 weeks. Participation in the trial will last a total of approximately 68 weeks (4 weeks screening (+/1 week) + 52 weeks treatment + 12 weeks follow up). Patients must be willing to remain on their established pre-study medication for COPD, throughout the study. Subject may be compensated $110 for each completed visit and all pre-study medication will be covered by the sponsor.
• Must be 40-85
• Diagnosis of COPD for at least 1 year
• May be a current or former smoker
• No other lung condition or diseases, including asthma

Inhaler (1)